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Abstract: Changes in the plasma metabolic profile were characterised in newly diagnosed rheumatoid
arthritis (RA) patients upon commencement of conventional disease-modifying anti-rheumatic drug
(cDMARD) therapy. Plasma samples collected in an early RA randomised strategy study (NCT00920478)
that compared clinical (DAS) disease activity assessment with musculoskeletal ultrasound assessment
(MSUS) to drive treatment decisions were subjected to untargeted metabolomic analysis. Metabolic
profiles were collected at pre- and three months post-commencement of nonbiologic cDMARD.
Metabolites that changed in association with changes in the DAS44 score were identified at the
three-month timepoint. A total of nine metabolites exhibited a clear correlation with a reduction
in DAS44 score following cDMARD commencement, particularly itaconate, its derived anhydride
and a derivative of itaconate CoA. Increasing itaconate correlated with improved DAS44 score and
decreasing levels of C-reactive protein (CRP). cDMARD treatment effects invoke consistent changes
in plasma detectable metabolites, that in turn implicate clinical disease activity with macrophages.
Such changes inform RA pathogenesis and reveal for the first time a link between itaconate production
and resolution of inflammatory disease in humans. Quantitative metabolic biomarker-based tests of
clinical change in state are feasible and should be developed around the itaconate pathway.
Keywords: rheumatoid arthritis; DMARD; macrophage; itaconate; inflammation; liquid
chromatography–mass spectrometry (LC-MS); biomarker discovery; tricarboxylic acid (TCA) cycle;
precision medicine
1. Introduction
Rheumatoid arthritis (RA) is a chronic, destructive, immune-mediated inflammatory condition
that predominantly affects synovial joints. In genetically susceptible individuals, mucosal exposure
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to external stimuli (e.g., cigarette smoke) triggers persistent systemic autoimmunity, and subsequent
inflammatory cell articular recruitment, leading to tissue damage [1]. Constitutional features, such as
weight loss, malaise or fever are prevalent in RA patients and RA patients exhibit an increased resting
metabolic rate [2], which may in part be related to increased immune cell activation and turnover.
Many data now suggest that circulating leukocyte subsets exhibit altered phenotypic and functional
properties in the context of RA [3]. Chronic synovitis is associated with angiogenesis and, consequently,
increased mediator release, e.g., prostanoids and chemokines that may be detected in the circulation.
Cardiometabolic disease is a common comorbidity, reflected particularly in dysregulation of lipid
metabolism [4] and has been attributed to an interaction between conventional risk factor pathways
and systemic pro-inflammatory cytokines [1]. Thus, it is possible that changes in disease activity state
may be reflected in measurable changes in biochemical activity that is demonstrated through detailed
characterisation of metabolite profiles.
Metabolomic technologies provide a detailed description of the relative abundance of individual
metabolites within a single tissue or biological system [5,6]. At an individual level, these metabolomic
“signatures” are the final expression of a complex process of gene-environmental interactions, gene
and inflammatory cell activation and protein synthesis [5]. Analysing metabolomic profiles across
a group of individuals can offer insights into disease pathogenesis when common associations with
clinical phenotype emerge. The increased ability to measure quantities of a wide range of different
metabolites has permitted detailed description of metabolic profiles across a range of complex,
polygenic disorders [7]. Nuclear Magnetic Resonance (NMR) and Liquid Chromatography coupled to
Mass Spectrometry (LC-MS) based metabolomics are being increasingly employed to understand the
biochemical changes associated with RA [5,8–15]. NMR metabolomics is capable of directly providing
identity and absolute concentration for a small number of metabolites. LC-MS is not capable of directly
providing absolute concentrations, but can have a larger coverage of the metabolome. For example,
plasma metabolic profiles, obtained using 1H-NMR, differentiated patients with different RA disease
activity and showed treatment with TNF-α inhibitors modified the baseline metabolic profiles associated
with active RA to resemble those of patients in remission [16]. Further, serum metabolite profiles
obtained using 1H-NMR at baseline, and at 24 weeks after treatment, also distinguished responders
from non-responders to methotrexate treatment [17].
Herein, we used an LC-MS platform to characterise changes in the plasma metabolomic profile
in newly diagnosed RA patients commencing first-line nonbiologic conventional disease-modifying
antirheumatic (cDMARD) therapy. Through an untargeted approach, we aimed to determine whether
the levels of individual metabolites correlated to disease activity following initiation of treatment and
whether changes in disease activity were also reflected in changes in the level of certain metabolites.
2. Results
2.1. Study Population
The baseline and 3-month characteristics of the patients included in this study are summarised in
Table 1. In this study, DAS44 was calculated using erythrocyte sedimentation rate (ESR). At baseline,
75 patients commenced methotrexate and four commenced sulphasalazine. After three months of
follow-up, we detected a significant improvement in disease activity, with a mean reduction in DAS44
from baseline of 2.1 (SD 1.4). Thirty-five patients were exposed to corticosteroid treatment (one oral,
nine intra-articular only, 19 intramuscular only, six intra-articular and intramuscular) prior to donating
research blood samples.
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Table 1. Baseline characteristics and disease activity outcomes of metabolomics cohort (n = 79).
Demographics
Female Sex, n (%) 54 (68%)
Age (y) 56 ± 13
Disease Duration (months) 5.3 ± 3.1
Rheumatoid Factor Positive, n (%) 51 (65%)
Anti-CCP Positive, n (%) 43 (53%)
Plain X-ray Erosions, n (%) 26 (33%)
Disease Activity Outcomes Baseline 3 Months
DAS44 4.5 ± 1.2 2.3 ± 1.3
HAQ 1.5 ± 0.8 0.9 ± 0.9
ESR 36 ± 26 21 ± 21
CRP 42 ± 55 14 ± 25
Unless stated, values are mean ± SD. anti-cyclic citrullinated peptides (anti-CCP); disease activity score in 44 joints
(DAS44); health assessment questionnaire (HAQ); erythrocyte sedimentation rate (ESR); C-reactive protein (CRP).
2.2. Metabolomic Analysis
Plasma from patients was subjected to untargeted metabolomics analysis using LC-MS [18].
A PCA plot (Supplementary File S1) reveals no appreciable global separation from baseline to three
months. Nevertheless, some individual peak changes were evident and those relating to the biggest
differentiators in the PCA loadings were checked against lists of common contaminants [19] and
assessed chromatographically as a safeguard against the observed separation being due to a sample
handling/processing factor.
2.3. Metabolite Comparisons
Comparisons were performed between individual peaks at baseline and three months, to see if
there were any significant differences. These comparisons used a basic t-test to calculate a p-value and
log fold-change difference. The p-values were used to control the false discovery rate, by calculating
q-values. Those differences with a value of q < 0.05 were reported as significant. Out of 3042 peaks in
the dataset, 464 were reported as different between baseline and three months. These values can be
seen in the accompanying spreadsheet (Supplementary File S2).
2.4. Relationship between Changes in Metabolite Levels and Changes in DAS44
To determine whether changes in disease activity were matched by changes in metabolomic
profile, differences in DAS44 and metabolite levels between time points were calculated, for all patients.
Linear regression was then performed, regressing DAS44 change on change in peak levels, for the
baseline to three months. Each set of regressions admitted an effect size and p-value. These p-values
were used to control the false discovery rate by calculating q-values.
Between baseline and three months, nine significant effects were found for values of q < 0.05.
A volcano plot of all the peaks is shown in Figure 1, with information on the significant peaks in Table 2.
Indicative plots of these data and models are shown in Figure 2. For example, looking at the model for
Peak.n.724, the slope of the line is −0.5, which indicates that a doubling/halving of the concentration
after treatment is associated with an extra change in DAS44 downwards/upwards of approximately
0.5. This extra change is on top of the average DAS44 change in the whole population. Once identified
as significant effects, these signals were manually assessed to determine peak quality and identity
(where possible).
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Figure 1. Volcano plot between baseline and three months. Blue points are significant peaks; orange 
points are not significant peaks. 
 
Figure 2. Scatter plots demonstrating change in DAS44 between baseline and 3 months vs. change in 
log2 peak intensity of 8 putative metabolites. The Itaconate peak (Peak 255) has been identified. Peaks 
1072 and 302 have been given putative identities of Itaconate anhydride and Itaconyl-CoA, 
respectively. 
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Figure 1. Volcano plot between baseline and three months. Blue points are significant peaks; orange
points are not significant peaks.
Table 2. Annotated LC-MS peaks that have been differentially expressed across changing DAS44 scores.
Peak ID Peak Changeq-Value m/z RT (s) Comments
Peak.n.724 0.0141 134.0579 477 Peak check passed. No ID
Peak.n.1157 0.0364 281.7499 204 Peak check passed. No ID
Peak.n.572 0.0364 466.3118 208 Peak check passed. Putative ID: cholesterol sulphate
Peak.n.302 0.0364 130.0267 435 Peak check passed. Putative ID: Itaconyl-CoA fragment,based on not matching standards for itaconic acid or isomers
Peak.n.1072 0.0364 112.0161 429 Peak check passed. Putative ID: ITACONIC-ANHYDRIDE
Peak.n.255 0.0234 130.0266 658
Peak check passed. Multiple peaks. Putative ID: Itaconate,
Metabolomics Standards Initiative level 1, based on
retention time and monoisotopic mass
Peak.n.1082 0.0364 467.3151 208 Peak check passed. Isotope of 572
Peak.p.133 0.0444 263.1115 616 Peak check passed. PEPTIDE_856, PEPTIDE_1100
Peak.p.209 0.004 481.3169 279 Peak check passed. Putative ID: lysoPC(15:0)
Foremost among those metabolites associated with the decline in DAS44 score were itaconate
(m/z = 130.0266), a predicted itaconate anhydride (m/z = 112.016), and a fragment predicted as
originating from itaconyl-CoA (130.0267) (Figure 3). Among the other metabolites were cholesterol,
several peptides and a range of fatty acids.
In order to verify the feature-by-feature analysis, a partial least-squares (PLS) analysis was performed
on the peak change of the full set of features against change in DAS44. This analysis indicated one
component and zero orthogonal components. The Q2Y metric was given as 0.125, with a p-value of 0.01
after 1000 permutations f th samples. The top nine features from this analysis corresponded exactly
to the nine features given by the feature-by-feature an lysis.
These results were then checked against those peaks that had a significant difference between
baseline and three months, to find those peaks where there was both a significant difference between
peak levels in the population, and also where there was a correlation between the change in DAS44
and the difference in peak levels. There were three peaks with this property, Peak.p.133 (annotated
as ser-ser-ala or gly-ser-thr), Peak.p.209 (annotated as LPC (15:0)) and Peak.n.1157 (mass of 281.7499,
Metabolites 2020, 10, 241 5 of 12
retention of 204 s). n.1157 was not matched to any known metabolite, it presents as a doubly charged
[M − 2H−]2− peak with a predicted formula of C30H61N9O.
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Figure 3. Metabolic pathway showing the tion and itaconate via the TCA cycle and metabolism
to pyruvate via itaconyl-CoA and citramalyl-CoA. Cis-aconitate is produced from citrate and isocitrate
by aconitase (AC). This is converted to itaconate by cis-aconitate decarboxylase (cADC) which is then
converted to itaconyl-CoA via succinate thiokinase (STK). Itaconyl-CoA is converted to citramalyl-CoA
by methylglutaconyl-CoA hydratase (MGTK) which is then converted to pyruvate and acetyl CoA [20].
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2.5. Itaconate and CRP Level Have Similar Predictive Power for Response
Blood CRP levels are measures of the acute phase response that have rapid change properties that
can map with response to treatments. Accordingly, it is included as an indirect surrogate of immune
cell activation and has been included in a number of composite disease activity measures such as
DASCRP-28 and SDAI. In this study, change in CRP levels correlated positively with a change in DAS44
score (r = 0.41, p = 1.2 × 10−3), diminishing as disease activity reduced. Conversely, change in itaconate
correlated negatively with a change in DAS44 (r = −0.49, p = 9.6 × 10−5). Besides being correlated with
DAS44, CRP and itaconate are also negatively correlated (r = −0.44, p = 4.9 × 10−4), as are ESR and
itaconate (r = −0.38, p = 3.6 × 10−3). These associations are shown in Figure 4. As ESR is a factor in the
calculation of DAS44, and ESR correlates with CRP, it is to be expected that there will be a correlation
between CRP and DAS44. However, the higher significance of the relationship between Itaconate and
DAS44 indicates that it might be more important than CRP in predicting DAS44 and hence patient
status. It was also found that there was no apparent correlation between change in itaconate and
change in the Health Assessment Questionnaire (HAQ) measure (r = −0.18, p = 1.7 × 10−1).
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Figure 4. Scatter plots showing correlation between (a) change in CRP between baseline and 3 months
vs. change in DAS44 between baseline and 3 months (r = 0.41); (b) change in itaconate between
baseline and 3 months vs. change in DAS44 between baseline and 3 months (r = −0.49); (c) change
in itaconate level between baseline and 3 months vs. change in CRP between baseline and 3 months
(r = −0.44); (d) change in itaconate between baseline and 3 months vs. change in ESR between baseline
and 3 months (r = −0.38).
3. Discussion
Metabolomics is emerging as a tool to identify biomarkers for disease, response to treatment and
also indicators of pathogenesis that may offer routes for novel interventions. In the past few years,
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a number of studies using both NMR and mass-spectrometry-based approaches have been applied to
study RA [5–17,21–23]. The use of an untargeted LC-MS platform has several benefits over the use of
other platforms, such as NMR. Whilst the reproducibility and quantitation provided by NMR allows
standardisation across laboratories, the technique is hampered by poor sensitivity and the inevitable
overlap of strong signals (such as water) with weak ones (including many metabolites of interest).
Mass spectrometry is capable of detecting, and identifying, a much broader range of metabolites and
combining it with a suitable LC set up optimised for small, polar metabolites will provide a much
more complete picture of the metabolome [18]. Mass spectrometry also allows for better identification
of unknown metabolites; signals that do not match a known metabolite in any of the databases [24].
We, therefore, adopted this approach to seek novel biomarkers of state and response in patients with
new-onset RA.
Our results demonstrate a clear association between short-term changes in DAS44 scores and
levels of a panel of nine metabolites. Principal amongst these is itaconate, its derived anhydride and a
putative itaconate CoA derivative. Further, the correlation between the DAS44 score and itaconate is
slightly more robust than that between the DAS44 score and CRP, indicating the itaconate might be as
good a marker of improved patient status as CRP (both, however, remaining less good than DAS44
score alone).
Itaconate has recently emerged as a primary moiety of interest in the pathogenesis of inflammatory
disease and macrophage activation to an M1/inflammatory phenotype. Initially, an ability to inhibit
succinate oxidation by succinate dehydrogenase was proposed as the key driver on its immunomodulatory
effect [25]. Recently however, it has been shown that itaconate impacts directly on the anti-inflammatory
transcription factor Nrf2 [26,27] to underpin its immunomodulatory activity. Itaconate is also the
most pronounced marker of inflammatory arthritis in a murine model [28]. A recent study in the
Tg197 murine model of inflammatory arthritis described itaconate to be a key marker of the disease,
and elevated levels were found in afflicted mice that reversed upon TNF blockade with infliximab [28].
In other studies, itaconate appears to be involved in the regulation of inflammation, its elevation
leading, ultimately, to suppression of the inflammatory response [29] and although functional roles
in human inflammatory disease have yet to be reported, our studies indicate levels are elevated as
inflammation is diminished.
Our data reveals increasing itaconate associated with decreasing DAS score after cDMARD
(primarily methotrexate) treatment, which is consistent with its anti-inflammatory role. However,
the analysis in Tg197 mice indicated that elevated levels of itaconate were found during disease
manifestation and these declined upon anti-inflammatory treatment with the anti-TNFα monoclonal
antibody, infliximab. This observation appears to be contradictory to ours. However, a number of
differences between the studies need to be considered. Our work used human plasma while hind
limb tissue extracts and synovial fibroblast extracts were found to be the optimal material to find
metabolite changes in the transgenic mouse model. Our first comparison point to baseline came at three
months while the mouse comparator point was at six weeks and our study did not include a cohort of
healthy controls to compare itaconate levels at the start of the experiment. Comparing cDMARD based
therapy and biological-based therapy may be another confounding factor since different therapies
work via different mechanisms to diminish inflammation and, therefore, may have differing influences
on itaconate levels. Notwithstanding, having demonstrated a clear link between itaconate levels and
response to treatment in RA, future studies using a wider range of variables will ultimately reconcile
our understanding of the role of this pathway in inflammatory disease.
This study cannot distinguish whether itaconate production is a result of improved condition
due to treatment or is in itself responsible for that improved condition. Nor can it determine what
impact exposure to specific treatments has on itaconate expression. In this study, the majority (95%) of
patients received methotrexate as first-line DMARD; however, the results cannot distinguish whether
the observed changes are related to the influence of changes in disease activity, or the direct effect of
methotrexate, on itaconate expression. The initial observation requires validation in an independent
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RA cohort, in patients treated with other DMARD and biologic therapies, and within cohorts of
patients with other inflammatory diseases. However, as the first indication that there is a clinically
evident association between itaconate levels and disease activity levels, the need for additional work
to understand if stimulating itaconate production pharmacologically offers a route to intervention
in RA is of major importance. The findings suggest that further study of the itaconate pathway and
macrophage activity may reveal additional important insights into immune function regulation and
RA pathogenesis and may also reveal new, clinically relevant, markers of disease activity and treatment
response. Finally, this study provides proof of concept that additional insights to disease pathogenesis
can be identified through analysis techniques that combine highly detailed descriptions of metabolite
expression with clinical data.
4. Materials and Methods
4.1. Study Population
This study was conducted using clinical data and samples from 79 patients recruited to the Targeting
Synovitis in Early Rheumatoid Arthritis (TaSER) study, a randomised clinical trial that compared the
effectiveness of using either clinical (DAS28) or musculoskeletal ultrasound (MSUS) assessment of
disease activity to drive an intensive early treatment strategy [30,31]. Briefly, at recruitment, all patients
had active RA (DAS44 > 2.4) and both groups followed the same step-up sequence of DMARD
escalation. In the DAS28 group, treatment was escalated until low disease activity was attained
(DAS28 < 3.2) and in the MSUS group treatment was escalated until 1 or no joints of a limited
14 MSUS joint set exhibited any power Doppler (PD) signal. At the start of treatment patients were
treated with methotrexate, or sulphasalazine if methotrexate was contraindicated, and combinations
of intra-articular and intramuscular corticosteroids. Disease activity assessments, using the 44-joint
disease activity score (DAS44), were conducted at baseline and every 3 months by a metrologist (AS)
who was blinded to group allocation and treatment. The earliest that study group allocation could
influence ongoing treatment was after 3 months of follow-up. The study protocol was approved by
the West of Scotland Research Ethics Service (09/S0709/38) and was registered with ClinicalTrials.Gov
(NCT00920478). All patients provided written consent to participate and for their disease activity
results and tissue samples to be used for research purposes. All study activities were conducted in
accordance with the Declaration of Helsinki.
4.2. Sample Collection and Preparation
All patients donated additional blood samples for research purposes at baseline (Group A)
and 3 months (Group B) using a standard operating procedure for sample harvest and processing.
Blood was collected into lithium heparin vacutainers and stored on ice. Samples were centrifuged at
4 ◦C (1100× g, fixed angle rotor) within 4 hours of venipuncture and 500 uL aliquots of plasma were
stored at −80 ◦C until required for analysis.
4.3. Metabolomics
Samples were analysed by hydrophilic interaction liquid chromatography (HILIC)-mass
spectrometry (LC-MS) (UltiMate 3000 RSLC (Thermo Fisher, San Jose, CA, USA) using a 150 × 4.6 mm
ZIC-pHILIC column (Merck SeQuant, Umea, Sweden) running at 300 ll/min and Orbitrap Exactive
(Thermo Fisher, San Jose, CA, USA) detection. Mass spectrometer parameters were: 50,000 resolving
power in positive/negative switching mode. Electrospray ionisation (ESI) voltage was 4.5 kV in positive
and 3 kV in negative modes. Buffers consisted of A: 20 mM ammonium carbonate in H2O and B: Merck
SeQuant: acetonitrile. The gradient ran from 20% A: 80% B to 80% A: 20% B in 900 s, followed by a
wash at 95% A: 5% B for 180 s, and equilibration at 20% A: 80% B for 300 s.
The LC-MS data were processed using a combination of open-source tools run though
R. Vendor-specific raw LC-MS files were converted into the mzXML open format using MSConvert from
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the proteowizard pipeline [32]. During conversion, the m/z data was centroided. Chromatographic
peaks were extracted from the mzXML files using the centwave detection algorithm from XCMS and
converted to PeakML files. Subsequently, PeakML files representing replicates were aligned and
combined using mzMatch.R [33] after filtering out all peaks that were not reproducibly detected within
groups. The combined PeakML files were subjected to additional intensity filtering, noise filtering and
gap-filling to produce a set of reproducible peaks. These peaks were then corrected for instrument drift
over time using an in-house Gaussian process regression algorithm modelled on the pooled samples.
Peaks were manually checked for consistency and integrated using QuanBrowser (Thermo Fisher
San Jose, CA, USA) where appropriate. Identifications were based on the Metabolomics Standards
Initiative proposed minimum reporting standards.
4.4. Statistical Analysis
Demographic and disease activity outcome data were collected from the TaSER study records.
Tests of significant differences between peak levels were calculated using t-tests and controlled
for by correcting the p-values for multiple testing by calculating q-values. Relationships between
disease activity and metabolite levels were modelled using linear regressions and tests of significance
were controlled by calculating q-values. Correlation coefficients were calculated using Pearson’s
product-moment method. Full metabolome correlation analysis was performed using partial least-squares
analysis of the full set of features on DAS44. Statistically highlighted features were manually assessed
for peak shape to determine if they correspond to genuine metabolite related signals. Metabolite
identification was carried out by first calculating an accurate molecular formula for the m/z value
within 3 ppm. This formula was then compared to a list of authentic standards and assigned as a
match if the retention time and peak shape were comparable. The list of authenticated standards is
included as supplementary material (Supplementary File S3). If not found in the authentic standards
a putative assignment was made based on the retention time of the feature and the chemistry of
the LC column using a curated list of 41,623 metabolites contained within the IDEOM database
(http://mzmatch.sourceforge.net/ideom.html), as detailed by Creek et al. [34]. The study dataset has
been uploaded to the online Metabolights repository (https://www.ebi.ac.uk/metabolights/MTBLS1583).
5. Conclusions
This study provides further support to the emerging view that itaconate has a regulatory role in
inflammation and inflammatory disease. The study has shown that it is feasible to conduct analyses
that combine sequential clinical outcome and metabolite expression data to identify novel biomarkers
of disease state and gain additional insight into chronic, inflammatory disease pathogenesis. The results
demonstrate an association between short-term, dynamic changes in rheumatoid arthritis disease
activity and a panel of nine metabolites. Of these metabolites, changes in itaconate level particularly
(and its derivatives) demonstrated a consistent negative correlation with changes in disease activity
level (measured by DAS44-ESR) and CRP. These findings suggest a clinically relevant association
between itaconate and rheumatoid arthritis disease activity and support further research into the role
of itaconate in rheumatoid arthritis pathogenesis.
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